Adenocarcinoma of Lung, Stage IV Recruiting Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Adenocarcinoma of Lung Stage IV / Lung adenocarcinoma stage IV / Adenocarcinoma Lung Stage IV / Stage IV Lung Adenocarcinoma / Lung adenocarcinoma metastatic / Adenocarcinoma of lung, stage IV (disorder)

IndicationStatusPhase
DBCOND0087327 (Adenocarcinoma of Lung, Stage IV)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05503667Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaTreatment